<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>Comments on: CLK2 inhibitor candidates</title>
	<atom:link href="https://thesgc.github.io/static-openlabnotebooks/clk2-inhibitor-candidates/feed/" rel="self" type="application/rss+xml" />
	<link>https://thesgc.github.io/static-openlabnotebooks/clk2-inhibitor-candidates/</link>
	<description>A growing team of groundbreaking scientists around the world are now sharing their lab notebooks online</description>
	<lastBuildDate>Wed, 15 Jan 2020 19:13:08 +0000</lastBuildDate>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>https://wordpress.org/?v=4.9.13</generator>
	<item>
		<title>By: Carla Alamillo-Ferrer</title>
		<link>https://thesgc.github.io/static-openlabnotebooks/clk2-inhibitor-candidates/#comment-97</link>
		<dc:creator><![CDATA[Carla Alamillo-Ferrer]]></dc:creator>
		<pubDate>Mon, 16 Jul 2018 15:17:25 +0000</pubDate>
		<guid isPermaLink="false">https://thesgc.github.io/static-openlabnotebooks/?p=1466#comment-97</guid>
		<description><![CDATA[Tim, there are inhibitors out there. For example TG003 which has an IC50 of 20 nM, 200 nM, and 15 nM for CLK1, CLK2, and CLK4, or T3, a compound from Takeda Pharmaceutical, with an IC50 of 0.67 nM and 15 nM for  CLK1 and CLK2 (find more info here: DOI 10.1038/s41467-016-0008-7). The next step is going to be the generation of the IC50 curves for CLK1 and CLK4,  to see if we can actually make a difference between the family.]]></description>
		<content:encoded><![CDATA[<p>Tim, there are inhibitors out there. For example TG003 which has an IC50 of 20 nM, 200 nM, and 15 nM for CLK1, CLK2, and CLK4, or T3, a compound from Takeda Pharmaceutical, with an IC50 of 0.67 nM and 15 nM for  CLK1 and CLK2 (find more info here: DOI 10.1038/s41467-016-0008-7). The next step is going to be the generation of the IC50 curves for CLK1 and CLK4,  to see if we can actually make a difference between the family.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Tim Willson</title>
		<link>https://thesgc.github.io/static-openlabnotebooks/clk2-inhibitor-candidates/#comment-94</link>
		<dc:creator><![CDATA[Tim Willson]]></dc:creator>
		<pubDate>Fri, 13 Jul 2018 16:45:15 +0000</pubDate>
		<guid isPermaLink="false">https://thesgc.github.io/static-openlabnotebooks/?p=1466#comment-94</guid>
		<description><![CDATA[Carla, it looks like you are close to having a chemical probe for CLK2. How do the best compounds compare with other known CLK2 inhibitors?]]></description>
		<content:encoded><![CDATA[<p>Carla, it looks like you are close to having a chemical probe for CLK2. How do the best compounds compare with other known CLK2 inhibitors?</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Carla Alamillo-Ferrer</title>
		<link>https://thesgc.github.io/static-openlabnotebooks/clk2-inhibitor-candidates/#comment-85</link>
		<dc:creator><![CDATA[Carla Alamillo-Ferrer]]></dc:creator>
		<pubDate>Fri, 06 Jul 2018 22:48:42 +0000</pubDate>
		<guid isPermaLink="false">https://thesgc.github.io/static-openlabnotebooks/?p=1466#comment-85</guid>
		<description><![CDATA[Matthieu, DiscoverX use immobilized promiscuous kinase inhibitors. Our test compounds compete for the active site and displace ligand if they are good inhibitors. If our compounds are no good they act like DMSO/buffer and show up as 100% of control. More info: https://www.discoverx.com/technologies-platforms/competitive-binding-technology/kinomescan-technology-platform]]></description>
		<content:encoded><![CDATA[<p>Matthieu, DiscoverX use immobilized promiscuous kinase inhibitors. Our test compounds compete for the active site and displace ligand if they are good inhibitors. If our compounds are no good they act like DMSO/buffer and show up as 100% of control. More info: <a href="https://www.discoverx.com/technologies-platforms/competitive-binding-technology/kinomescan-technology-platform" rel="nofollow">https://www.discoverx.com/technologies-platforms/competitive-binding-technology/kinomescan-technology-platform</a></p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Matthieu Schapira</title>
		<link>https://thesgc.github.io/static-openlabnotebooks/clk2-inhibitor-candidates/#comment-84</link>
		<dc:creator><![CDATA[Matthieu Schapira]]></dc:creator>
		<pubDate>Fri, 06 Jul 2018 20:21:41 +0000</pubDate>
		<guid isPermaLink="false">https://thesgc.github.io/static-openlabnotebooks/?p=1466#comment-84</guid>
		<description><![CDATA[Carla, could you explain the readout of Kinome Scan? Is it the % of inhibition relative to a potent inhibitor serving as positive control?]]></description>
		<content:encoded><![CDATA[<p>Carla, could you explain the readout of Kinome Scan? Is it the % of inhibition relative to a potent inhibitor serving as positive control?</p>
]]></content:encoded>
	</item>
</channel>
</rss>
